Amylyx Pharmaceuticals, Inc. (AMLX)
38.14
-0.52
(-1.35%)
USD |
NASDAQ |
Aug 24, 16:00
38.14
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Debt to Equity Ratio : 0.022 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.022 |
| March 31, 2026 | 0.0206 |
| December 31, 2025 | 0.0195 |
| September 30, 2025 | 0.0179 |
| June 30, 2025 | 0.0355 |
| March 31, 2025 | 0.0069 |
| December 31, 2024 | 0.012 |
| September 30, 2024 | 0.0131 |
| June 30, 2024 | 0.012 |
| March 31, 2024 | 0.0114 |
| December 31, 2023 | 0.0098 |
| September 30, 2023 | 0.0114 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0137 |
| March 31, 2023 | 0.0164 |
| December 31, 2022 | 0.0184 |
| September 30, 2022 | 0.0469 |
| June 30, 2022 | 0.0367 |
| March 31, 2022 | 0.0298 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.0023 |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.267 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Pfizer Inc. | 0.7418 |
| Eli Lilly & Co. | 1.621 |
| Merck & Co., Inc. | 1.286 |
| EyePoint, Inc. | 0.1344 |
| Bristol Myers Squibb Co. | 2.019 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 264.56M |
| Total Liabilities (Quarterly) | 25.40M |
| Shareholders Equity (Quarterly) | 239.17M |
| Current Ratio | 12.12 |
| Net Debt Paydown Yield | -0.04% |